Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 7:55 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–19 of 19 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Generic Tacrolimus Clear all
Recruiting Phase 2 Interventional

Advancing Transplantation Outcomes in Children

NCT06055608
View directory record Official record
Conditions
Kidney Transplant
Interventions
Sirolimus, Belatacept, Mycophenolate Mofetil, Tacrolimus (Group1), Anti-Thymocyte Globulin (ATG), Tacrolimus (Group 2)
Drug · Biological
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
13 Years to 20 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
20
States / cities
Birmingham, Alabama • Los Angeles, California • San Diego, California + 15 more
Source: ClinicalTrials.gov public record
Updated May 19, 2026 · Synced Sep 12, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

Crossover Study to Compare PK of Once Daily LCP-Tacro Tablets to Generic Tacrolimus Capsules Twice Daily.

NCT01962922
View directory record Official record
Conditions
Renal Failure
Interventions
LCP-Tacro, Tacrolimus -IR
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
3
States / cities
Chicago, Illinois • St Louis, Missouri • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 5, 2018 · Synced Sep 12, 2026, 7:55 PM EDT
Terminated Phase 4 Interventional Results available

Myfortic or CellCept Gastrointestinal Effects in African American Kidney Recipients

NCT00522548
View directory record Official record
Conditions
Transplants and Implants
Interventions
Enteric coated mycophenolate sodium, Mycophenolate mofetil
Drug
Lead sponsor
University of Pennsylvania
Other
Eligibility
18 Years to 75 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 22, 2018 · Synced Sep 12, 2026, 7:55 PM EDT
Completed Phase 2 Interventional

Envarsus XL Immunosuppression Following Liver Transplantation

NCT03828058
View directory record Official record
Conditions
Recipients of Liver Transplant
Interventions
Envarsus XR, Prograf
Drug
Lead sponsor
Methodist Healthcare - Memphis
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jan 11, 2021 · Synced Sep 12, 2026, 7:55 PM EDT
Completed Phase 4 Interventional Results available

Pharmacokinetics of Generic to Brand Tacrolimus in Stable Renal Transplant Patients

NCT01256294
View directory record Official record
Conditions
Renal Transplant
Interventions
Generic Tacrolimus, Branded Tacrolimus
Drug
Lead sponsor
Novartis
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
2
States / cities
Cincinnati, Ohio • Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 20, 2012 · Synced Sep 12, 2026, 7:55 PM EDT
Completed Phase 2 Interventional

LEA29Y (Belatacept) Emory Edmonton Protocol

NCT00468403
View directory record Official record
Conditions
Type 1 Diabetes Mellitus
Interventions
Allogeneic Pancreatic Islet Cells, Belatacept, Basiliximab, Mycophenolate Mofetil, Tacrolimus, Intraportal infusion of islet cells
Biological · Drug · Procedure
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2013
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Apr 6, 2016 · Synced Sep 12, 2026, 7:55 PM EDT
Completed Phase 4 Interventional

Pharmacokinetic Studies of Tacrolimus in Transplant Patients

NCT01889758
View directory record Official record
Conditions
Kidney Transplant Recipients, Liver Transplant Recipients
Interventions
Prograf, Tacrolimus
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
78 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
2
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 21, 2016 · Synced Sep 12, 2026, 7:55 PM EDT
Completed Phase 3 Interventional

To Study Generic Tacrolimus Ointment, 0.1% in the Treatment of Moderate to Severe Atopic Dermatitis (Inflammation of Skin: Itchy, Red, Swollen, and Cracked Skin)

NCT02601703
View directory record Official record
Conditions
Atopic Dermatitis
Interventions
Tacrolimus Ointment 0.1%, Protopic® ointment, 0.1%, Placebo of Tacrolimus Ointment
Drug
Lead sponsor
Glenmark Pharmaceuticals Ltd. India
Industry
Eligibility
18 Years and older
Enrollment
1,110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
60
States / cities
Tempe, Arizona • Anaheim, California • Bell Gardens, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 30, 2019 · Synced Sep 12, 2026, 7:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Effects of Altered Formulation on the Bioequivalence of Tacrolimus in Healthy Female and Male Volunteeers

NCT02341274
View directory record Official record
Conditions
Bioequivalence
Interventions
Tacrolimus
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 49 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Apr 6, 2023 · Synced Sep 12, 2026, 7:55 PM EDT
Terminated Phase 2 Interventional Results available

Optimization of NULOJIX® Usage Towards Minimizing CNI Exposure in Simultaneous Pancreas and Kidney Transplantation

NCT01790594
View directory record Official record
Conditions
Simultaneous Kidney and Pancreas Transplantation
Interventions
Belatacept, methylprednisolone, Anti-thymocyte Globulin (Rabbit), Tacrolimus, Mycophenolate mofetil
Biological · Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 55 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
5
States / cities
Birmingham, Alabama • San Francisco, California • Atlanta, Georgia + 2 more
Source: ClinicalTrials.gov public record
Updated Jul 19, 2021 · Synced Sep 12, 2026, 7:55 PM EDT
Completed Phase 4 Interventional Results available

Envarsus in Delayed Graft Function (E-DGF)

NCT03864926
View directory record Official record
Conditions
Delayed Graft Function
Interventions
Envarsus XR, Tacrolimus
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 19, 2023 · Synced Sep 12, 2026, 7:55 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Bioequivalence Study of Tacrolimus in Healthy Volunteers

NCT04725682
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Tacrolimus
Drug
Lead sponsor
Food and Drug Administration (FDA)
Federal
Eligibility
18 Years to 59 Years
Enrollment
67 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 20, 2023 · Synced Sep 12, 2026, 7:55 PM EDT
Completed Phase 4 Interventional Results available

Prospective Study Comparing Brand and Generic Immunosuppression on Transplant Outcomes, Adherence, & Immune Response in Kidney Transplant Recipients

NCT02866682
View directory record Official record
Conditions
Renal Transplant Rejection
Interventions
Prograf, Tacrolimus
Drug
Lead sponsor
University of California, Los Angeles
Other
Eligibility
18 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Apr 27, 2023 · Synced Sep 12, 2026, 7:55 PM EDT
Completed Phase 3 Interventional Results available

Switching Study of Kidney Transplant Patients With Tremor to LCP-Tacro (STRATO)

NCT01438710
View directory record Official record
Conditions
Renal Failure, Tremors
Interventions
Prograf, LCP-Tacro
Drug
Lead sponsor
Veloxis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
10
States / cities
Los Angeles, California • San Diego, California • Aurora, Colorado + 7 more
Source: ClinicalTrials.gov public record
Updated Sep 30, 2015 · Synced Sep 12, 2026, 7:55 PM EDT
Recruiting Phase 2 Interventional

Belatacept in Heart Transplantation

NCT06478017
View directory record Official record
Conditions
Heart Transplant
Interventions
Belatacept, Tacrolimus, Mycophenolate Mofetil/Sodium, Prednisone
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 71 Years
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
6
States / cities
Los Angeles, California • Tampa, Florida • Atlanta, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 12, 2026, 7:55 PM EDT
Completed Phase 4 Interventional Results available

To Compare the Effects of Immediate-release Tacrolimus and Astagraf XL on Donor-Specific Antibody (DSA) Formation and the Development of Immune Activation (IA) in de Novo Kidney Transplant Recipients

NCT02723591
View directory record Official record
Conditions
Kidney Transplantation
Interventions
Tacrolimus, Tacrolimus immediate release
Drug
Lead sponsor
Astellas Pharma Global Development, Inc.
Industry
Eligibility
16 Years to 70 Years
Enrollment
599 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
30
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 24 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2024 · Synced Sep 12, 2026, 7:55 PM EDT
Completed No phase listed Observational

Extended Follow-Up After Islet Transplantation in T1D

NCT01369082
View directory record Official record
Conditions
Type 1 Diabetes (T1D), Islet Transplantation
Interventions
Maintenance Immunosuppressive Treatment
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
8
States / cities
San Francisco, California • Miami, Florida • Atlanta, Georgia + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 8, 2017 · Synced Sep 12, 2026, 7:55 PM EDT
Completed Phase 2 Interventional Results available

Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients

NCT03663335
View directory record Official record
Conditions
Kidney Transplantation
Interventions
CFZ533 - Cohort 1/Cohort 2, Mycophenolate Mofetil (MMF), Corticosteroids (CS), Tacrolimus, Induction therapy: basiliximab, Induction therapy: rabbit anti-thymocyte globulin (rATG), Maintenance population: EC-MPS, Maintenance population: MMF, Placebo 1 mL
Biological · Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2021
U.S. locations
15
States / cities
Los Angeles, California • San Francisco, California • Aurora, Colorado + 10 more
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced Sep 12, 2026, 7:55 PM EDT
Completed Phase 4 Interventional Results available

Conversion From Brand to Generic Tacrolimus in High Risk Transplant Recipients

NCT02014103
View directory record Official record
Conditions
Complication of Transplant
Interventions
Prograf, Tacrolimus, Sandoz, Tacrolimus, Reddy Laboratory, Tacrolimus, Mylan, Tacrolimus, Accord, Tacrolimus, Pancea Biotech Limited
Drug
Lead sponsor
University of Cincinnati
Other
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 14, 2024 · Synced Sep 12, 2026, 7:55 PM EDT